Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

rosuvastatin calcium

This page shows the latest rosuvastatin calcium news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca settles with generic rivals in Crestor patent challenge

AstraZeneca settles with generic rivals in Crestor patent challenge

The company said it has entered into a settlement agreement with Actavis and Egis Pharmaceuticals over their plan to launch generic Crestor (rosuvastatin calcium), blocking competition for the product until May ... Actavis (formerly Watson Pharma) filed

Latest news

  • Crestor can't top Lipitor in head-to-head study

    A study comparing the effects of AstraZeneca's Crestor (rosuvastatin calcium) with Pfizer's Lipitor (atorvastatin calcium) in has found no difference between the statin drugs in preventing the progression of ... The SATURN trial was designed to look at

  • AZ's Q3 income up as sales stay flat

    The company said more than $350m of revenue was lost due to generic competition, cancelling out strong performances for statin Crestor (rosuvastatin calcium), antipsychotic Seroquel XR (quetiapine fumarate) and Symbicort

  • AstraZeneca partners with cooking website

    AstraZeneca (AZ) has entered into a partnership with Food University, a web-based culinary platform, to help educate consumers about healthy eating in support of the company's medication Crestor (rosuvastatin ... calcium), which is approved to lower

  • AZ sees decrease in Q4 profit

    Revenue for the year remained flat at around $33bn. Well-performing drugs for the company included cholesterol product, Crestor (rosuvastatin calcium), with the drug seeing a revenue increase of 26 per

  • Generics and legal costs affect AZ profits

    The company reported double-digit sales growth for cholesterol drug Crestor (rosuvastatin calcium), for which AZ has filed a law suit against Watson Pharmaceuticals in an effort to block the company

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest appointments

  • Evan Lippman joins Aileron Therapeutics Evan Lippman joins Aileron Therapeutics

    Highlights of his career include a spell as executive director at AstraZeneca where he led on huge brands such as Crestor (rosuvastatin calcium) and Nexium (esomeprazole) and heading US business development

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Quick links

Infographics

Multimedia